NCT07031713View on ClinicalTrials.gov

Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 16, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

March 31, 2027

Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
BIOLOGICAL

CAR-T Therapy

CT1192 cells infusion

Trial Locations (1)

430000

Wuhan Union Hospita, Wuhan

Sponsors
All Listed Sponsors
collaborator

CARsgen Therapeutics Co., Ltd.

INDUSTRY

lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER